Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line.
A human Epstein-Barr virus-transformed B-cell line (IC.1) was characterized for cell surface antigen profile and permissivity to immunodeficiency virus (HIV) infection. According to cocultivation assay with MT2 cells, P24 release, and immunofluorescence assay, complement-sufficient serum enhanced in vitro infection of IC.1 cells. Enhancement occurs independently of the presence of HIV type 1-specific antibodies, although more efficiently when they are present. Blocking experiments with monoclonal antibodies demonstrated that complement receptor type 2 mediates this phenomenon and that the CD4 molecule is required for infection. Enhancement of in vitro infection on IC.1 cells appears closely related to previously described complement-mediated, antibody-dependent enhancement of HIV infection on the T-lymphoblastoid cell line MT2 (W. E. Robinson, Jr., D. C. Montefiori, and W. M. Mitchell, Lancet i:790-794, 1988).
Gras
G S
GS
Laboratoire de Neuropathologie Expérimentale et Neurovirologie, CRSSA, DSV/DPTE, Commissariat à l'Energie Atomique, Fontenay aux Roses, France.
Dormont
D
D
D000911:Antibodies, Monoclonal / Q000276:immunology*; D000954:Antigens, Surface / Q000032:analysis*; D001402:B-Lymphocytes / Q000276:immunology*; D002460:Cell Line; D002472:Cell Transformation, Viral; D003165:Complement System Proteins / Q000276:immunology*; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D015483:HIV Antibodies / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology* / Q000502:physiology; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006801:Humans; D014779:Virus Replication
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D015483:HIV Antibodies; D015488:HIV Antigens; D003165:Complement System Proteins